BioForest
Filter News
Found 15,765 articles
-
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
5/22/2018
TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has expanded its recently formed Scientific Advisory Board (SAB) and will support the continued clinical development of the Company's transformative, non-genetically engineered, multi-antigen T cell therapy platform.
-
Minnesota Protects Patients with New Step Therapy Bill
5/21/2018
National Psoriasis Foundation Leads Effort to Pass Step Therapy Reform
-
Although it may be almost heresy to say it to venture capitalists and many research scientists, there are other places in the U.S. to form biotech companies than San Francisco and Boston.
-
Seattle Genetics Appoints Roger D. Dansey, M.D., Chief Medical Officer
5/17/2018
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Roger D. Dansey, M.D., as Chief Medical Officer. Dr. Dansey brings extensive experience in cancer drug development, most recently from Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types.
-
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
5/15/2018
TapImmune Inc. (NASDAQ: TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
-
Accelerator Life Science Partners Broadens its Leadership Teams and Expands its Geographic Operations to San Diego and the Greater Los Angeles Area
5/15/2018
Newly formed Operating Partners group and Clinical and Scientific Advisory Board to provide critical insights to support portfolio companies’ success and guide investment strategies
-
AGC Biologics enters into Commercial Supply Agreement with MacroGenics
5/10/2018
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, for the manufacture of margetuximab, a clinical-stage, novel immune-optimized monoclonal antibody.
-
SeptiCyte™ LAB Differentiates Sepsis from SIRS in the ICU
5/9/2018
Design and results of clinical trials that led to FDA clearance of SeptiCyte™ LAB published in the American Journal of Respiratory and Clinical Care Medicine
-
Bardy Diagnostics™ Announces Validation of AI-Enabled Automatic Screening Technology for Atrial Fibrillation
5/9/2018
Bardy Diagnostics, Inc. is the provider of the world's only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device
-
Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
5/7/2018
Presentation will be Webcast Live and Archived on Vanda's Website
-
Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
BioLife Solutions to Report First Quarter 2018 Financial Results and Provide Business Update on May 10, 2018
5/3/2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon
-
Urgent Medical Device Recall: SAM XT Extremity Tourniquet
5/2/2018
SAM Medical today announced it is conducting a voluntary international recall of all unused SAM XT Extremity Tourniquets (SAM XT)
-
Seattle Genetics to Present at the Bank of America Merrill Lynch Health Care Conference 2018
5/2/2018
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018 at 5:00 p.m. Pacific Time
-
Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease
5/2/2018
Proprietary system to be used to reprogram patients’ cells to produce treatment
-
BIO Statement on Release of USTR’s 2018 Special 301 Report
5/1/2018
The Biotechnology Innovation Organization (BIO) issued a statement.
-
LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
5/1/2018
LumiThera Inc. presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.
-
New Study Finds Lupus Is A Leading Cause Of Death Among Young Women
5/1/2018
A recent study led by UCLA researchers found that lupus is among the leading causes of death in young women.
-
National Alliance for Hispanic Health joins NIH in launching the All of Us Research Program with Event in Pasco, WA
5/1/2018
The National Institutes of Health (NIH) on May 6, 2018 is opening national enrollment for the All of Us Research Program.